National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 239-249

  Kang, Min H ^a   Smith, Malcolm A ^b   Morton, Christopher L ^c   Keshelava, Nino ^d   Houghton, Peter J ^e   Reynolds, C Patrick ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Cell line models; Childhood cancer; Cytotoxicity; DIMSCAN; NCI PPTP

Indexed keywords

ETOPOSIDE; MELPHALAN; RAPAMYCIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOMATION; BRAIN TUMOR; CANCER CELL CULTURE; CANCER MODEL; CELL COUNT; CHILDHOOD CANCER; CURVE FITTING; DIGITAL IMAGING; DRUG CYTOTOXICITY; EWING SARCOMA; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; NATIONAL HEALTH ORGANIZATION; NEUROBLASTOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHILD; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; HUMANS; MELPHALAN; NATIONAL CANCER INSTITUTE (U.S.); SIROLIMUS; UNITED STATES; VINCRISTINE;

EID: 78650108430     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22801     Document Type: Article

References (46)

1. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: Meeting summary. Clin Cancer Res 2002; 8: 3646-3657.
2. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
3. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004; 64: 5415-5424.
4. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001; 61: 6185-6193.
5. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008; 14: 4572-4583.
6. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007; 67: 32-40.
7. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
8. Kurmasheva R, Morton C, Houghton PJ. Developing new agents for the treatment of childhood cancer. Curr Opin Investig Drugs 2005; 6: 1215-1227.
9. McAllister RM, Melnyk J, Finkelstein JZ, et al. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 1969; 24: 520-526.
10. Petak I, Douglas L, Tillman DM, et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000; 6: 4119-4127.
11. Hazelton BJ, Houghton JA, Parham DM, et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 1987; 47: 4501-4507.
12. Rodriguez-Perales S, Martinez-Ramirez A, de Andres SA, et al. Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet 2004; 148: 35-43.
13. Leggas M, Stewart CF, Woo MH, et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 2002; 8: 3000-3007.
14. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403.
15. Xu J, Reynolds CP. Novel cell lines from pediatric brain tumors showed striking multi-drug resistance. Proc Am Assoc Cancer Res 2006; 47: 4348 (Abstract).
16. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990; 86: 1806-1814.
17. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997; 3: 423-431.
18. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-5405.
19. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000; 45: 1-8.
20. Hurwitz R, Hozier J, LeBien T, et al. Characterization of a leukemic cell line of the pre-B phenotype. Int J Cancer 1979; 23: 174-180.
21. Stong RC, Korsmeyer SJ, Parkin JL, et al. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
22. Sheard MA, Kang MH, Cabral D, et al. Bone marrow-level oxygen tension enables enhanced and sustained growth of 3 new pediatric acute lymphoblastic leukemia cell lines. Proc Am Assoc Cancer Res 2007; 48: 1808 (Abstract).
23. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972; 49: 891-895.
24. Foley GE, Lazarus H, Fabber S, et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965; 18: 522-529.
25. Asou H, Tashiro S, Hamamoto K, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031-2036.
26. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988; 72: 234-240.
27. Benjamin D, Magrath IT, Maguire R, et al. Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J Immunol 1982; 129: 1336-1342.
28. Klein G, Giovanella B, Westman A, et al. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 1975; 5: 319-334.
29. Grigoryan R, Keshelava N, Anderson C, et al. In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol Med 2005; 110: 87-100.
30. Keshelava N, Frgala T, Krejsa J, et al. DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005; 110: 139-153.
31. Masters JR, Thomson JA, ly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98: 8012-8017.
32. Parson W, Kirchebner R, Muhlmann R, et al. Cancer cell line identification by short tandem repeat profiling: Power and limitations. FASEB J 2005; 19: 434-436.
33. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319.
34. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten-+/--mice. Proc Natl Acad Sci USA 2001; 98: 10320-10325.
35. Law BK, Chytil A, Dumont N, et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002; 22: 8184-8198.
36. Reaman GH. Pediatric cancer research from past successes through collaboration to future transdisciplinary research. J Pediatr Oncol Nurs 2004; 21: 123-127.
37. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424-1431.
38. Harrison S. Perspective on the history of tumor models. In: Teicher BA, editor. Tumor models in cancer research. Totowa, NJ: Humana Press; 2002. pp. 3-19.
39. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 42-48.
40. Kolb EA, Gorlick R, Houghton PJ, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor sorafenib. Proc Am Assoc Cancer Res 2009; 50: 3196 (Abstract).
41. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1198-1206.
42. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: A t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005; 46: 247-255.
43. Beghini A, Magnani I, Ripamonti CB, et al. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: A t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002; 3: 157-163.
44. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-3395.
45. Gorlick R, Kolb EA, Houghton PJ, et al. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 594-598.
46. Monga M, Sausville EA. Developmental therapeutics program at the NCI: Molecular target and drug discovery process. Leukemia 2002; 16: 520-526.